|
DIRECT |
Direct myocardial revascularization |
|
|
Laser trial for Class III IV angina |
|
SAFER |
SVG extraction type catheter |
|
VORTEX |
For use in saphenous vein bypass interventions |
|
Iliac Stent |
IVT stent versus conventional treatment for iliac
stenosis |
|
A to Z |
Chest pain patients who receive Aggrastat, Heparin,
and ASA. |
|
|
Can have intervention immediately or Aggrastat must
run for at least 12
|
|
|
hours after intervention. Then patients are started
on ZOCOR. |
|
Acute 2 |
Lovenox/TEE/Cardioversion |
|
Madit II |
AICD post MI with Ef<30% |
|
Target Trial |
Cath lab study, Double Blind use of Aggrastat and
ReoPro |
|
ACS Multi-Link |
5-year follow-up on patients who received ACS
Multi-Link 3 years ago |
|
AVE GFX Stent |
5-year follow-up for AVE GFX stents |
|
SUPORT |
Boston Scimed stents versus ACS stents |
|
CONSERVE |
IVT low-pressure stent versus Guidant stent |
|
LP Stent |
LP versus Guidant stent |
|
HERMES |
Renal stents |
|
SAPPHIRE |
High-risk randomized trial CEA vs. Stent with
Distal Protection |
|
ARCHER |
Carotid stents in High Risk PTS Non-randomized |
|
CRUISE |
Integrilin with Enoxaparin |
|
PRESTO |
Prevention of Restenosis with Tranilast |
|
SIRIUS |
Drug-coated Stent to Prevent Restenosis |
|
LIMIT |
Brachytherapy to Prevent Restenosis |
|
SAPHIRE |
Carotid Stent with Filter to Prevent Embolization |
|
CREST |
NIH Sponsored Comparing CEA to Carotid Stent with
Distal
|
|
|
Protection � Low-risk patients |
|
VEGAS |
Evaluation of Angiojet for Saphenouse Vein Graft
Disease |
|
LACI |
Excimer Laser for Critical Limb Ischemia |
|
ARCHER |
High-risk Non-randomized Carotid Stent with Distal
Protection |
|
CARESS |
Randomized Carotid Stent Trial for Low-risk |
|
DELIVER |
Randomized Coated Stent Trial to Reduce Restenosis |